Genetic Determinants of CYP2C19 Gene *2 and *3 Loss of Function Alleles and Response to Anti Platelet Therapy (Clopidogrel) and Cardiovascular Events. (A Study in Kashmir, North India)

Irfan Ahmad Bhat¹, Arshad A. Pandith², Irfan Yaqoob, Shehjar Faheem, Imran Hafeez, Jahangir R Beig, Zafar A. Shah and Khurshed Iqbal*

SK Institute of Medical Sciences, Srinagar-190011, Jammu and Kashmir, India

**Summary**

**Background:** Studies have demonstrated that the *2 and *3 allele of the CYP2C19 loss-of-function polymorphism is associated with diminished metabolization of clopidogrel and an attenuated platelet response to clopidogrel treatment. Since no such study has been conducted in this region, we examined CYP2C19 polymorphism in Acute Coronary Syndrome (ACS) patients on clopidogrel treatment, and its effect on the cardiovascular outcomes.

**Material and Methods:** A total of 100 samples of ACS were included in this study and genotyping of CYP2C19 *2 and *3 gene polymorphisms was performed by a Polymerase chain reaction-Restriction fragment length polymorphism (PCR-RFLP).

**Results:** The distribution of CYP2C19*2 allele wild *1/*1, Heterozygous *1/*2 and homozygous mutant *2/*2 genotypes was 56%, 34% and 10% respectively while for CYP2C19*3 wild*1/*1 and heterozygous *1/*3 genotypes were 84% and 16% respectively. The frequency of compound heterozygotes (*2/*3) was found in 9% (90 of 100 patients). CYP2C19 *1/*2 allele was found in 03 of 34 (8.8%) patients who had CV events followed by 2 of 10 (20%) patients with mutant genotype CYP2C19*2 (*2/*2) on follow up. In the CYP2C19*3, 31.2% having heterozygous genotype (*1/*3) had CV events as compared to 11.9% with *1/*1 (31% vs 11.9% p>0.05). In the poor-metabolizer group (*2/*2 or *2/*3), 20.1% of patients had CV events on follow up compared to 15.6% in the extensive metabolizer group (*1/*1), whereas in the intermediate group only 10% of patients had CV events (p>0.05).

**Conclusion:** We conclude that patients carrying CYP2C19 loss-of-function alleles had a higher rate of subsequent cardiovascular events as against those with normal allele. Lack of significant events even in presence of variant alleles justifies us to some extent to continue clopidogrel in our patients.

**Keywords:** Acute Coronary syndrome; CYP2C19; Clopidogrel; Poor-metabolizer; Allele

**Introduction**

The hepatic CYP2C19 enzyme contributes to the metabolism of many clinically relevant drugs such as antidepressants, benzodiazepines, mephenytoin, some proton pump inhibitors, and clopidogrel. Like many other CYP450 superfamily members, the CYP2C19 gene is highly polymorphic, having more than 25 known variant alleles (http://www.cypalleles.ki.se/cyp2c 19.htm). CYP2C19 *1 represents the wild-type allele. On the basis of their ability to metabolize (S)-mephenytoin or other probe drugs, individuals can be categorized as Extensive Metabolizer (EM), PM (Poor Metabolizer or Ultra rapid Metabolizer (UM) for CYP2C9. Heterozygous EMs are sometimes also referred to as Intermediate Metabolizer (IMs) [1]. The majority of the CYP2C9 PMs are carriers of the variant alleles *2 and *3, which are loss of function alleles (LOF) whereas the *17 variant is a gain of function (GOF) allele associated with increased activity [2]. Studies have shown a marked interethnic variation in the distribution of variant alleles. The allelic frequency of CYP2C19*2 has been shown to be 15% in Africans, 29–35% in Asians, 12–15% in Caucasians and 61% in Oceanians. The CYP2C19*3 is mainly found in Asians (5–9% in Asians, less than 0.5% in Caucasians). The allelic frequency of CYP2C19*17 has been shown to be 16% in Africans, 3–6% in Asians and 16–21% in Caucasians [3].

Clopidogrel is a prodrug whose in vivo metabolite binds to the platelet P2Y12 receptor causing irreversible blockade. The pharmacodynamic response to clopidogrel has substantial inter patient variability [4-7] and patients with coronary disease with lesser degrees of platelet inhibition in response to clopidogrel appear to be at increased risk for cardiovascular events [7-9]. Approximately 85% of the parent drug is inactivated by human carboxylesterase 1, whereas the remainder is transformed to the intermediate, inactive oxo-clopidogrel by CYP2C19, CYP1A2 and CYP2B6 [10].

Clopidogrel is an antiplatelet drug used in atherothrombotic diseases, such as myocardial infarction and stroke, which is an inactive prodrug that needs to be bioactivated by a liver enzyme, CYP2C19. Several loss-of-function alleles have been previously identified [11]. CYP2C19*2 and CYP2C19*3 are the two most frequent variants in Occidentals and Asians, respectively. Major cardiovascular events occur two- to three-times more frequently in patients treated with clopidogrel having decreased CYP2C19 function compared with wild-type patients after myocardial infarction, stent thrombosis [12-14]. A gene-dose effect seems to occur with the patients heterozygous for one CYP2C19 variant showing an intermediate clinical response between wild-type patients and patients homozygous for the loss-of-function
variants [12]. Identification CYP2C19 alleles with reduced function has also been associated with reduced responsiveness to, and thus reduced therapeutic benefit of, clopidogrel in cardiovascular patients [12,15-19]. The presence of CYP2C19 loss of function alleles *2 and *3 may result in lower exposure to Clopidogrel and thus decreased platelet inhibition in clopidogrel treated patients [20]. For this reason FDA issued a Boxed Warning to the clopidogrel label to stress upon the need to identify patients with CYP2C19 alleles classified as PMs who are considered at an increased risk of adverse cardiovascular outcomes due to reduced effectiveness of clopidogrel [21]. A systematic review and meta-analysis was conducted to examine the association between CYP2C19 genotype and the clinical efficacy of clopidogrel where it was shown that the presence of at least one loss of function allele was associated with an increased risk of stent thrombosis [22]. Owing to the established role of CYP2C19 genotype and its relation in anti-platelet (Clopidogrel) therapy, the guiding principles for clopidogrel dosing is still a matter of debate. Besides, ethnic difference exists in both pharmacokinetics and pharmacodynamic and they play an important role in optimization of therapy for the individual patient and drug administration. Since no such study has been conducted in this part, so our investigation will examine the CYP2C19 polymorphism in our patients on clopidogrel treatment, and its effect on the cardiovascular outcomes in patients with Acute Coronary Syndrome.

Methodology

This study was conducted in Sher-i-Kashmir Institute of Medical Sciences, (Jammu and Kashmir, India) in the Department of cardiology, Immunology and Molecular Medicine and Advanced Centre for Human Genetics for a period of 2 years. Clearance from local SKIMS ethical committee was taken prior to study.

Study subjects

A total of 100 samples were included in this study which comprised of confirmed cases of ACS which were selected from Department of Cardiology, SKIMS. Blood samples were taken from the patients after a written pre informed consent was obtained. Demographic and clinic-pathological characteristics of each patient were recorded in a Questionnaire. Patients were followed over a period of 2 years and clinic-pathological characteristics of each patient were recorded after a written pre informed consent was obtained. Demographic and clinical characteristics of patients are shown in Table 1 and the results obtained are presented in five categories of observations including demographic characteristics, the presence or absence of diabetes, hypertension, smoking and BMI.

DNA extraction and polymerase chain reaction (PCR)

2-5 ml of blood sample was taken from each patient and stored at -20°C for DNA analysis. Genomic DNA was isolated using standard proteinase-K digestion, phenol/chloroform extraction, and ethanol precipitation method from whole-blood samples of both cases and controls. The primers used were Cyp19*2 F-5’ AAATTTTCTTCAATCTTAAAGCT-3’ and R-5’ ACTTCAGGGCTTTGTCATAA-3’ whereas for Cyp19*3 F-5’ CAGAGCTT GGCA TATTGTAT C-3’ and R-5’ GTAAACACACAA ACTAGTCAA TG-3’ producing 321 bp and 271bp PCR products respectively. PCR was carried out in a final volume of 25 ul containing 50 ng genomic DNA template, 1x PCR buffer (Biotools, B and M Labs, Madrid, Spain) with 2 mmol/L MgCl₂, 0.4 mmol/L of each primer (Genscript, Piscataway, NJ), 50 mmol/L dNTPs (Biotools, B and M Labs), and 0.5 U Taq Polymerase (Biotools, B and MLabs). For PCR amplification, the standard protocol was used as follows: one initial denaturation step at 94°C for 7 minutes, followed by 35 denaturation cycles of 30 seconds at 94°C, 30 seconds of annealing at 53°C, and 30 seconds of extension at 72°C, followed by a final elongation cycle at 72°C for 5 minutes.

Restriction Fragment Length Polymorphism (RFLP)

Two principle alleles of CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893) were analyzed by PCR-RFLP. Exon 4 and Exon 5 of CYP2C19 were amplified by PCR that contain the CYP2C19 *2 and *3 polymorphisms respectively. 681G>A in Exon 5 of CYP2C19 (*2) creates an aberrant splice site and destroys Smal restriction site and 636G>A in CYP2C19*3 gene, creates a premature stop codon and abolishes BamHI restriction site. 10ul of PCR amplified DNA were digested with 5 Units of each Smal and BamHI (Fermentas Life Sciences, USA) restriction enzymes for both polymorphisms CYP2C19 *2 and *3 respectively while keeping the other conditions as per instructions of manufacturer. The digested products were electrophoresed using 2% agarose gel and visualized by Ethidium Bromide staining. The PCR products (271bp) of *3 yielded two bands of 175bp and 96bp in wild type and three products of 96, 175 and 271bp in heterozygous variants (Figure 1A). The PCR product (321bp) encompassing allele *2 digested into two smaller bands of 109bp and 212bp in wild type individuals whereas heterozygous variants for this allele yielded three bands of 321, 212 and 109bp and in homozygous variants the PCR product would not be digested (Figure 1B).

Genotyping classification

Patients were classified into different metabolizer phenotype groups. Patients with two CYP2C19*2 or CYP2C19*3 alleles (*2/2 or *2/*3) were classified as having the poor- metabolizer phenotype, those with one CYP2C19*2 or CYP2C19*3 allele (*1/*2 or *1/*3) were classified as having the Intermediate – metabolizer phenotype and those without CYP2C19*2 or CYP2C19*3 allele (*1/*1) were classified as having extensive-metabolizer phenotype.

Statistical Analysis

All continuous variables of study have been shown in terms of Mean ± SD and the categorical variables in terms of frequency and percentage. The standard statistical tests like T-test. Chi square test and Fisher exact test have been used to analyze the data, moreover odds ratio with 95% confidence interval have been calculated at appropriate places. All the results obtained have been discussed on 5% level of significance (p value<0.05) considered as significant, also suitable statistical charts have been used to represent the data, SPSS version 20 was used for analysis.

Results

The mean age of our patients was 61.1 ± 8 (range 43 to 75) and majority of patients belonged to age groups of 50-60(38%) and 60-70 years (39%) where 80% of patients were males and 20% females. Hypertension and diabetes mellitus was present in 84% and 39% of patients respectively. Our study included 71% patients with ST Elevation
Myocardial Infarction (STEMI), 20% Non-ST elevation Myocardial Infarction (NSTEMI) and 9% of patients were having unstable Angina (USA) Table 1.

Table 1 shows all the clinical details of Acute Coronary Syndrome (ACS) patients classified with cardiovascular events in different conditions. Ninety two patients went for Coronary Angiography (CAG) after Acute Coronary syndrome (ACS) while as in eight patients CAG could not be done due to financial constraints. Of the 92 patients 69 (75%) had single vessel disease (SVD), 13 (14%) of patients had double vessel disease (DVD) and 10 patients had triple vessel disease (TVD).

In our study 15 patients had Cardiovascular events (CV) on follow up in which there were 04 deaths (possible stent thrombosis), 06 patients had definite stent thrombosis, 02 patients had probable stent thrombosis (who presented with MI in the same territory), 02 patients had MI in the same territory who had not undergone percutaneous coronary intervention (PCI) after coronary angiography (CAG) and 01 patient had instant restenosis (ISR) and presented with ACS. The cardiovascular events were noticed over a study period mostly during the first year of follow up.

The distribution of CYP2C19*2 allele wild *1/*1 (no loss of function), heterozygous *1/*2 (Loss of function allele) and homozygous mutant *2/*2 (Total loss of function) genotypes were 56%, 34% and 10% respectively and CYP2C19*3 wild *1/*1, and heterozygous *1/*3 genotypes were 84% and 16% respectively. No patient had homozygous mutant *3/*3 genotype. The frequency of compound heterozygotes (*2/*3) was found in 9% (9 of 100 patients) Table 2.

Frequency distribution of CYP2C19*2 and CYP2C19*3 having different metabolizer phenotypes in ACS patients on clopidogrel and their relation to Cardiovascular Events are shown in detail in Table 3. CYP2C19 *1/*2 allele (loss of function allele) was found in 03 of 34 (8.8%) patients who had CV events, only 2 of 10 (20%) patients with mutant genotype CYP2C19*2 (*2/*2) had CV events on follow up and patients with wild genotype *1/*1, 10 of 56 (17.9%) had CV events. In the CYP2C19*3, 15 out of 16 patients (93.7%) having homozygous genotype (*1/*1) had CV events as compared to 10 out of 84 (11.9%) with *1/*1 type (31% v/s 11.9% p value 0.061). The distribution of these genotypes among the CV events did not match statistical significance (p<0.05) (Table 3).

In the poor-metabolizer group of patients 20.1% of patients had CV events on follow up compared to 15.6% in the extensive metabolizer group of patients, whereas in the intermediate group only 10% of patients had CV events (Figure 1). All these figures were not statistically significant (p <0.05) (Table 3).

**Discussion**

Clopidogrel is an antiplatelet drug used in atherothrombotic diseases, such as myocardial infarction and stroke, which is an inactive prodrug that needs to be bioactivated by a liver enzyme, CYP2C19. Several loss-of-function alleles have been previously identified [11]. CYP2C19*2 and CYP2C19*3 are the two most frequent variants in Occidentals and Asians, respectively. CYP2C19 alleles are associated with reduced conversion of clopidogrel to its active metabolite. Many studies support the observations regarding reduced-function of CYP2C19 polymorphisms and platelet aggregation among clopidogrel-treated subjects [20,23,24]. Ethnic difference also exists and they play an important role in optimization of therapy for the individual patient and drug administration. To our knowledge this study is the first from the subcontinent, to investigate the CYP2C19 polymorphism in our patients on clopidogrel treatment, and its effect on the cardiovascular outcomes in patients with acute coronary syndrome.

The present report observed frequency of wild CYP2C19*2, heterozygous *1/*2 and mutant homozygous *2/*2 genotypes as 56%, 34% and 10% respectively while as for CYP2C19*3 wild *1/*1 and heterozygous *1/*3 genotypes were 84% and 16% respectively. Homozygous mutant *3/*3 contributing for loss of function was not found in any case of our study. Nine percent (9%) were compound heterozygotes (*2/*3).

In a study conducted by Dirk et al. [14] on a large sample size, 1805 patients, (73%) were CYP2C19 wild-type homozygotes (*1/*1), 633 (25%) were CYP2C19*2 heterozygotes (*1/*2), and 47 (2%) were homozygous (*2/*2) for the mutant CYP2C19*2 allele. Despite comparatively small sample size, we observed high frequency of mutant CYP2C19*2 allele as against Dirk et al. (2% v/s 10% our study). Simon et al. [12] also observed the same pattern of CYP2C19*2 allele frequency as Dirk et al. [14] and thus both differing more on the frequency of mutant allele *2/*2 (2% Dirk et al. [14] v/s 2.5% Tabossam et al. [12] v/s 10% our study). For CYP2C19*3 allele, although genotype distribution frequency differs from our report (*1/*1; 84%, *1/*3; 16% our study v/s 99% and 1% Tabossam et al. [12]) but both studies report a similar finding where no subject were having mutant (*3/*3) genotype. Prasanthi et al. [25] in northeastern patients of India found 36%, 24% for *1/*1 and *1/*2 respectively with CYP2C19*2 allele and 60% in CYP2C19*3 had *1/*1 genotype which show a complete disagreement with our cohort giving a more evidence for the ethnic difference of this polymorphic gene.

Our patients carrying CYP2C19*2 heterozygous allele *1/*2 had 8.8% CV events and homozygous mutant genotype *2/*2 carriers had 20% against 17.9% CV events in patients with wild genotype *1/*1. Likewise genotype *1/*3 in CYP2C19*3 had 31.2% CV events as compared 11.9% with *1/*1 (31% v/s 11.9%), however, all these figures did not match statistical significance thus disagreeing with many studies [20, 24].

In the poor-metabolizer group of patients 20.1% of patients had CV events on follow up compared to 15.6% in the extensive metabolizer group of patients, whereas in patients in the intermediate group only 10% of patients had CV events. All these figures were not statistically
Table 1: Clinical details of Acute Coronary Syndrome (ACS) patients classified with cardiovascular events in different conditions. STEMI: ST Elevation Myocardial Infarction, NSTEMI: Non-ST Elevation Myocardial Infarction, USA: Unstable Angina, SVD: Single Vessel Disease, DVD: Double Vessel Disease, TVD: Triple Vessel Disease, LV: Left Ventricular, MI: Myocardial infarction, PCI: percutaneous coronary intervention

Table 2: Frequency of genotypes with CYP2C19*2 and CYP2C19*3.

significant (p > 0.05) and these results were consistent with study of Guillame [19].

The previous studies other than conducted by Guillame et al. [19] had shown attenuated benefits of clopidogrel among carriers of loss of function alleles. Our study matched the results of the study conducted by Guillame et al. [19], although poor metabolizer group of patients had increased frequency of CV events than extensive metabolizer group but could not achieve significance. All these results can be explained to some extent by potential pleotropic effects of loss of function alleles (independent of their effects on active metabolite of clopidogrel). Moreover since variation of non-CYP genes may also have effect on responsiveness to clopidogrel and the likelihood of ischemic events.

Despite increased prevalence of heterozygous and mutant allele in our population, we could not see significant CV events in our patients on the basis of CYP2C19*2 and CYP2C19*3 alleles (loss of function alleles), which justifies us to some extent to continue clopidogrel in our patients, the majority of which belong to low economic class who may not be able to afford the antiplatelet agents like prasugrel and ticagrelor. The FDA has added boxed warning to clopidogrel which is for patients who do not effectively metabolize the drug (poor metabolizers). However this study with comparatively less sample size prompts us to enroll more patients to elucidate whether such approach can be applied to the patients of this geographical area.

Conclusion

We conclude that patients carrying CYP2C19 loss-of-function alleles had a higher rate of subsequent cardiovascular events as against those
Table 3: Frequency distribution of CYP2C19*2 and CYP2C19*3 having different metabolizer phenotypes in ACS patients on clopidogrel and their relation to cardiovascular events.

| Metabolizer Phenotype | Genotype       | Cardiovascular Event | Total | P VALUE |
|-----------------------|----------------|----------------------|-------|---------|
|                       | CYP2C19*2      |                      |       |         |
|                       | (rs4244285)    |                      |       |         |
| *1/*1 (GG)            | NO             | 46(82.1%)            | 56    | 0.460   |
|                       | YES            | 10(17.9%)            |       |         |
| *1/*2 (AG)            | NO             | 31(91.1%)            | 34    |         |
|                       | YES            | 03(8.8%)             |       |         |
| *2/*2 (AA)            | NO             | 8(80%)               | 10    |         |
|                       | YES            | 2(20%)               |       |         |
| TOTAL                 |                | 85                   | 15    | 100     |
|                       | CYP2C19*3      |                      |       | 0.61    |
| (rs4986893)           | *1/*1 (GG)     | 74(88.1%)            | 84    |         |
|                       | *1/*3 (AG)     | 11(68.8%)            | 16    |         |
| TOTAL                 |                | 85(85%)              | 15(15%)| 100     |
|                       | Compound homozygote |                |       | 0.570   |
|                       | Extensive      | 43(84.4%)            | 51    |         |
|                       | Intermediate   | 27(90%)              | 30    |         |
|                       | Poor           | 15(78.9%)            | 04(20.1%)| 19  |         |
|                       | TOTAL          | 85                   | 15    | 100     |

Figure 2: Cardiovascular events in patients with Metabolizer phenotype

Extensive metabolizer (with genotype *1/*1), Intermediate metabolizer (with genotype *1/*2, *1/*3) and Poor metabolizers (with genotype *2/*2 and *2/*3).

Table 4: Frequency of CYP2C19*2 and CYP2C19*3 having different metabolizer phenotypes in ACS patients on clopidogrel and their relation to cardiovascular events.

with normal allele. These events in CYP2C19 loss-of-function alleles were particularly marked among the patients undergoing percutaneous coronary intervention. Lack of significant events even in presence of variant alleles justifies us to some extent to continue clopidogrel in our patients.

Acknowledgment

We acknowledge with warm thanks the cooperation of the patients of this study as well as the SKIMS administration for funding this study.

References

1. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, et al. (1998) Identification of New Human CYP2C19 alleles in a Caucasian poor Metabolizer of Mephenytoin. J Pharmacol Exp Ther 284: 356-361.
2. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, et al. (1997). Frequency distribution of CYP2C19*2 and CYP2C19*3 having different metabolizer phenotypes in ACS patients on clopidogrel and their relation to cardiovascular events. N Engl J Med 360: 354-362.
3. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, et al. (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19: 83-95.
4. Gurbel PA, Bilen KP, Hiatt BL, OConnor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2910-2913.
5. O'Donoghue M, Wiviott SD (2006) Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 114: e600-e606.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, et al. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49: 1505-16.
7. Metzky S, Shennok B, Ghosh J, Shechter M, Beinart R, et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175.
8. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, et al. (2006). Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48: 1742-1750.
9. Gurbel PA, Bilen KP, Samara W, Yoho JA, Hayes K, et al. (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46: 1827-1832.
10. Kazui M, Nishiyama Y, Ishizuka T, Hagihara K, Farid NA, et al. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38: 92-99.
11. Human CYP450 Allele Nomenclature Committee.
12. Simon T, Verslyuft C, Mary-Krause M, Quteineh L, Drouet E, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
13. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
14. Sibbing D, Stegherr J, Latz W, Koch W, Mehlli J, et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30: 916-922.
15. Farid NA, Khurana A, Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50: 126-142.
16. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119: 2553-2560.
17. Giusti B, Gori AM, Marucci R, Saracini C, Sestini I, et al. (2009) Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103: 806-811.
18. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, et al. (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30: 1744-1752.
19. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, et al. (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363: 1704-1714.
20. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, et al. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5: 2429-2436

21. FDA Drug Safety Communication (2010): reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug.

22. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, et al. (2011) Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343: d4588.

23. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, et al. (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51: 1925-1934.

24. Hulot JS, Bura A, Villard E, Azizi M, Remones V, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247.

25. Prasanthi SV, Jamdade VS, Bolshette NB, Gogoi R, Lahkar M (2014) Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. J Pharmacogenomics Pharmacoproteomics 5: 132.